.jpg)
.png)
How has your professional training and background shaped your career in lipids?
After completing Cardiology training in Boston, I worked under the mentorship of Dr. David Blankenhorn at the University of Southern California for 14 years. His expertise and passion for the field was instilled in me during this time – something I was able to bring back to Boston, where I have been at Mass General since 2004.
Article By:
Director of LDL Apheresis Unit
Massachusetts General Hospital
Harvard Medical School
Boston, MA
Diplomate, American Board of Clinical Lipidology
Assistant Professor of Biology
Fairfield University
Fairfield, CT
It is an exciting time to be the president of the National Lipid Association as we celebrate our 15th Anniversary. The successes and accomplishments of this and the past years are built on the strong leadership and counsel that we have enjoyed from the inception of the organization.
Article By:
NLA President, 2016-17
University of Pennsylvania Health
System - Retired
Philadelphia, PA
As practicing clinicians, we all continue to face the challenge of remaining up to date with the rapid pace of advancing science in our field. As I consider different options to accomplish this goal in 2017, none can compare to active participation in the wide variety of educational activities offered by the National Lipid Association. Our Annual Meeting and regional Clinical Lipid Updates are beacons of light that help us to focus on the newest clinical applications of lipidology science.
Article By:
NLA Past President, 2015-16
Associate Professor of Medicine
University of Miami School of Medicine
Miami, FL
Diplomate, American Board
of Clinical Lipidology
I’m always reminded of how fortunate I have been to serve the National Lipid Association (NLA) in various capacities and to watch the organization grow and mature over time. I have seen tremendous growth in member engagement in various NLA activities, as well as a renewed sense of comradery and purpose.
Article By:
Past President, NLA, 2014-15
Professor of Medicine
Director, Office of Health Promotion
& Disease Prevention
Emory University
Atlanta, GA
Diplomate, American Board
of Clinical Lipidology
I was asked to write a perspective on a look back of the past five years on the NLA and clinical lipidology. It is impossible to state all the advances made in clinical lipidology and the contributions our organization has made over the past five years in a short and focused perspective. Therefore, I decided to constrain my perspective to those advancements made in one of the highest risk populations, familial hypercholesterolemia (FH)-not surprising for those who know me well.
Article By:
NLA Past President, 2013-14
Sanofi DCV Medical Affairs
Sanofi US
Portland, OR
Lipid therapeutics over the past three decades have focused on oral drugs that targeted lipid metabolism through mechanisms that regulate clearance of apoprotein B-containing lipoproteins (through the LDL receptor, such as statins, bile acid resins and ezetimibe) or the synthesis/clearance of triglyceride-containing lipoproteins (such as fibrates, niacin and omega 3 fatty acids).
Article By:
Chief Science Officer
National Lipid Association
Associate Professor of Medicine
Co-Director, Lipid Metabolism & Atherosclerosis Clinic Center for Cardiovascular Disease Prevention
Houston Methodist DeBakey Heart & Vascular Center
Baylor College of Medicine
Houston, TX
Diplomate, American Board of Clinical Lipidology
Chief Executive Officer
National Clinical Research, Inc.
Manakin Sabot, VA
I am both honored and humbled to be chosen as your next president of SELA. I am fully aware I walk in the footsteps of giants in the field.
When reflecting on the direction of SELA over the next year, three words come to mind – diversity, disparities and dissemination. First, it is my hope that we can continue to increase our membership by inviting potential members of all eligible disciplines.
I am extremely honored and excited to be the President of the MWLA for this next year.
2017 has certainly been the year of change, whether speaking about politics, sports, or medicine. Change can be exciting, stimulating, but sometimes frightening when not prepared for the change.
Responses from healthcare workers show significant barriers to prescriptions
PCSK9 Inhibitors Survey Findings Infographic Download
PCSK9 Inhibitors Approval Checklist Download
James A. Underberg, MD, MS, Elected President during the 2017 NLA Scientific Sessions in Philadelphia
PHILADELPHIA, Pa. — The National Lipid Association (NLA) announced the election of new President James A. Underberg, MD, MS, FACPM, FACP, FASPC, FNLA, on Saturday at the 2017 Scientific Sessions in Philadelphia.
